Innovative Medicines Initiative (IMI 2)
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.276 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.
IMI was launched in 2008 and currently has 46 ongoing projects, with more in the pipeline. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects
Giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. IMI warmly encourages small and medium-sized enterprises (SMEs), medium-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.
IMI Success Stories
IMI2 Call 8: Next deadlines
Next cut-off dates for IMI2 Ebola+ call for proposals: 14/9/2017, 15/3/2018For more information
IMI2 Call 11
Deadline for submissions: 24/10/2017
Webinar: Call 11: Exploitation of IMI project results - Wednesday 26 July, 14.30-16:00 - Register here
IMI2 Call 12 - Future topics and webinars
1.Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)
2. FAIRification of IMI and EFPIA data
3. Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
4. European Health Data Network (EHDN)
5. Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
6. Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
7. European Screening Centre: unique library for attractive biology (ESCulab)
More information about the topics: http://www.imi.europa.eu/content/imi2-call-12
Opportunities for SMEs in Call 12: http://h2020.lt/wp-content/uploads/file/IMI2_C12_SME-Opportunities.pdf
Deadline for submissions: 24/10/2017
Find projects partners: Search for project partners via the Partner Search Tool: http://www.imi.europa.eu/content/partner-search
Presentations from the IMI Stakeholder Forum 2015